The Center said on Tuesday (November 17) that organizing the cold chain necessary to store the coronavirus vaccine candidate developed by Pfizer is a major challenge. It should be noted that the vaccine developed by Pfizer must be stored at a temperature of minus 70 degrees Celsius.
However, NITI Aayog (Health) member Dr VK Paul said the Center is looking into the possibilities if India has to get the vaccine developed by Pfizer. Kaul, who is also the head of the National Task Force on COVID-19, said that a nationwide COVID vaccine distribution scheme is currently in its final stages of preparation.
Paul noted that the arrival of the Pfizer vaccine will not arrive in India anytime soon. “Arranging cold chains to store the vaccine developed by Pfizer at a low temperature of minus 70 degrees Celsius is a huge challenge and will not be easy for any nation. But then, if it is to be sourced, we are examining what we have to do … and we will develop a strategy, “he said.
Speaking of the vaccine candidates from Moderna and Pfizer, Paul said: “We are watching developments. They have announced preliminary results and have not obtained regulatory approvals.”
Read: This is how a teaspoon of coronavirus has infected more than 50 million people
Kaul also said that five vaccines are currently in different phases of testing in the country and all of these vaccines are expected to show positive results. He noted that the doses of these vaccines will be available in sufficient quantities.
On live Tv
Meanwhile, American pharmaceutical giant Moderna announced Monday that its Covid-19 vaccine candidate is nearly 95% effective in preventing the deadly viral disease. The company also said it will produce 20 million doses of vaccines by the end of 2020. Previously, Pfizer had announced that it plans to produce about 50 million doses of vaccines in 2020.
.
